331 related articles for article (PubMed ID: 15647651)
21. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
22. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease.
Kaspari S; Kupcinskas L; Heinze H; Berghöfer P
Eur J Gastroenterol Hepatol; 2005 Sep; 17(9):935-41. PubMed ID: 16093871
[TBL] [Abstract][Full Text] [Related]
23. Esomeprazole: a review of its use in the management of acid-related disorders.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
[TBL] [Abstract][Full Text] [Related]
24. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.
Netzer P; Gut A; Brundler R; Gaia C; Halter F; Inauen W
Aliment Pharmacol Ther; 2001 Sep; 15(9):1375-84. PubMed ID: 11552908
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.
van Zyl JH; de K Grundling H; van Rensburg CJ; Retief FJ; O'Keefe SJ; Theron I; Fischer R; Bethke T
Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):197-202. PubMed ID: 10741935
[TBL] [Abstract][Full Text] [Related]
26. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Bochenek WJ; Mack ME; Fraga PD; Metz DC
Aliment Pharmacol Ther; 2004 Nov; 20(10):1105-14. PubMed ID: 15569113
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
28. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.
Plein K; Hotz J; Wurzer H; Fumagalli I; Lühmann R; Schneider A
Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):425-32. PubMed ID: 10783996
[TBL] [Abstract][Full Text] [Related]
29. One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis.
Mössner J; Koop H; Porst H; Wübbolding H; Schneider A; Maier C
Aliment Pharmacol Ther; 1997 Dec; 11(6):1087-92. PubMed ID: 9663834
[TBL] [Abstract][Full Text] [Related]
30. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
[TBL] [Abstract][Full Text] [Related]
31. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Langtry HD; Wilde MI
Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
[TBL] [Abstract][Full Text] [Related]
32. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
33. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Moraes-Filho JP; Pedroso M; Quigley EM;
Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
[TBL] [Abstract][Full Text] [Related]
34. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
Wilder-Smith C; Backlund A; Eckerwall G; Lind T; Fjellman M; Röhss K
Clin Drug Investig; 2008; 28(6):333-43. PubMed ID: 18479175
[TBL] [Abstract][Full Text] [Related]
35. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
36. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
Mulder CJ; Westerveld BD; Smit JM; Oudkerk Pool M; Otten MH; Tan TG; van Milligen de Wit AW; de Groot GH;
Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience with pantoprazole in gastroesophageal reflux disease.
Avner DL
Clin Ther; 2000 Oct; 22(10):1169-85; discussion 1149-50. PubMed ID: 11110229
[TBL] [Abstract][Full Text] [Related]
38. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
van Zyl J; van Rensburg C; Vieweg W; Fischer R
Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
[TBL] [Abstract][Full Text] [Related]
40. Prevention of erosive oesophagitis relapse with pantoprazole.
Richter JE; Fraga P; Mack M; Sabesin SM; Bochenek W;
Aliment Pharmacol Ther; 2004 Sep; 20(5):567-75. PubMed ID: 15339328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
